stockrow
Friday 6 November 2026
Export HYPR’s income statement to Excel — free account
Hyperfine, Inc.
HYPR Healthcare Medical Devices
Hyperfine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 5.22% from fiscal 2024.
- Revenue
- +44.8%
- EPS
- +25.0%
- Free cash flow
- +13.4%
Quarter to June 2026, against a year earlier
0.70
0.01
+1.45%
Follow HYPR
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.82 | 5.91 | 6.88 | 8.15 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.53) | (15.39) | (11.71) | (18.54) | |
P/B ratio |
4.26 | 1.95 | 3.07 | 3.67 | |
Price to Tangible BV |
4.26 | 1.95 | 3.07 | 3.67 | |
EV/Sales |
8.74 | 3.25 | 5.05 | 6.24 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.98) | (1.58) | (2.79) | (3.81) | |
EV/FCF |
(2.87) | (1.51) | (2.70) | (3.75) | |
Quick Ratio |
2.79 | 3.63 | 4.64 | 5.25 | |
Current Ratio |
3.63 | 4.34 | 5.52 | 6.15 | |
Net Debt/EBITDA |
2.55 | 4.88 | 3.41 | 3.90 | |
Debt/Assets |
0.00% | 0.00% | 21.75% | 21.01% | |
Debt/Equity |
0.00 | 0.00 | 0.38 | 0.36 | |
Asset Turnover |
0.19 | 0.24 | 0.27 | 0.31 | |
Operating CF/Net income |
0.51 | 0.88 | 1.04 | 0.78 | |
Capex/Depreciation |
(0.44) | (0.22) | (0.83) | (0.08) | |
Interest Coverage |
— | — | (103.11) | (15.89) | |
Research and Development Expense of Revenue |
117.78% | 72.27% | 98.51% | 99.00% | |
Selling, General and Administrative Expense of Revenue |
195.52% | 123.50% | 171.46% | 168.65% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
17.95% | 13.07% | 16.58% | 23.13% | |
Graham Net Nets |
0.19 | 0.46 | 0.28 | 0.24 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(35.86%) | (44.90%) | (37.96%) | (28.15%) | |
Free Cash Flow Yield |
(28.12%) | (36.34%) | (27.17%) | (20.43%) | |
Revenue per Share |
0.04 | 0.06 | 0.04 | 0.04 | |
Operating CF per Share |
(0.07) | (0.06) | (0.09) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.06) | (0.09) | (0.07) | |
Cash per Share |
0.28 | 0.44 | 0.42 | 0.45 | |
Shareholders Equity per Share |
0.34 | 0.50 | 0.35 | 0.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.34 | 0.50 | 0.35 | 0.37 | |
Free Cash Flow |
(5.71) | (5.27) | (9.25) | (7.30) | |
Working Capital |
26.74 | 39.18 | 45.88 | 49.61 | |
Capital Expenditures |
(0.13) | (0.06) | (0.24) | (0.03) | |
Net Current Asset Value |
22.26 | 36.65 | 30.06 | 33.00 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.01 | 0.06 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.69 | 7.41 | 6.53 | 6.37 | |
Average Payables |
2.56 | 2.83 | 3.43 | 2.70 | |
Average Inventory |
6.44 | 6.46 | 5.48 | 5.84 | |
Average Assets |
55.45 | 57.08 | 56.86 | 54.12 | |
Average Common Equity |
42.60 | 45.02 | 38.74 | 35.94 |
Columns are period end dates